Profund Advisors
CLDX icon

Profund Advisors’s Celldex Therapeutics CLDX Stock Holding History

Profund Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$814K Sell
25,116
-3,814
-13% -$146K 0.02% 417
2026
Q2 		$1.08M Sell
28,930
-596
-2% -$19.3K 0.03% 332
2026
Q1 		$937K Sell
29,526
-12,928
-30% -$352K 0.03% 363
2025
Q4 		$1.15M Buy
42,454
+21,149
+99% +$557K 0.04% 320
2025
Q3 		$551K Buy
21,305
+5,880
+38% +$136K 0.02% 482
2025
Q2 		$314K Sell
15,425
-7,220
-32% -$141K 0.01% 665
2025
Q1 		$411K Sell
22,645
-6,789
-23% -$152K 0.02% 544
2024
Q4 		$744K Buy
29,434
+10,873
+59% +$295K 0.03% 362
2024
Q3 		$631K Sell
18,561
-3,945
-18% -$150K 0.02% 444
2024
Q2 		$833K Sell
22,506
-7,841
-26% -$296K 0.03% 351
2024
Q1 		$1.27M Buy
30,347
+5,861
+24% +$241K 0.05% 296
2023
Q4 		$971K Sell
24,486
-3,553
-13% -$104K 0.04% 331
2023
Q3 		$772K Sell
28,039
-9,382
-25% -$294K 0.04% 345
2023
Q2 		$1.27M Buy
37,421
+10,049
+37% +$339K 0.07% 263
2023
Q1 		$985K Buy
+27,372
New +$1.18M 0.06% 305

Other funds holding CLDX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
TSP Capital Management Group
TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Ellsworth Advisors
Ellsworth Advisors Hudson, Ohio $620M AUM 38.17% 1-Year Est. Return
Apella Capital
Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Overbrook Management Corp
Overbrook Management Corp New York $643M AUM 29.06% 1-Year Est. Return

Profund Advisors's CLDX Position: Q3 2026 in Review

Profund Advisors reduced its Celldex Therapeutics (CLDX) stake by 13% in Q3 2026, selling an estimated $146K and leaving 25,116 shares worth $814K. The position accounts for 0.02% of the portfolio, ranked #417.

Profund Advisors first reported a position in CLDX in Q1 2023 and has held it in 15 quarters since. The position peaked at $1.27M in Q1 2024. 42 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Profund Advisors held 25,116 shares of Celldex Therapeutics worth $814K as of Q3 2026.
  • Profund Advisors sold 3,814 Celldex Therapeutics shares in Q3 2026, an estimated $146K.
  • Celldex Therapeutics made up 0.02% of Profund Advisors's portfolio in Q3 2026, its #417 holding.
  • Profund Advisors first reported a position in Celldex Therapeutics in Q1 2023 and has held it in 15 quarters since.
  • Profund Advisors's Celldex Therapeutics position peaked at $1.27M in Q1 2024.
  • 42 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.